Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in Immunocompromised CSCC
NCT04242173Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2020
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Moffitt Cancer Center. Started Jun 2020; status: terminated.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04242173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242173.